Gout in Severe Renal Impairment (eGFR <30 mL/min): When Allopurinol Has Not Achieved Serum Uric Acid Targets
Clinical Scenario
This protocol addresses patients with gout who have severe renal impairment — defined as an estimated glomerular filtration rate below 30 mL/min. At this level of renal function, the range of appropriate urate-lowering agents is specifically restricted, and standard first-line management may not reach required targets.
Previous Treatment: Goals Not Reached
First-line therapy consisted of allopurinol, with the maximum dosage adjusted to creatinine clearance, combined with appropriate lifestyle measures. This regimen did not achieve the required serum uric acid goals:
- Serum uric acid <6 mg/dL (360 mmol/L), maintained lifelong
- Serum uric acid <5 mg/dL (300 mmol/L) for patients with severe gout, until total crystal dissolution
The structured next-line protocol below applies once this failure is confirmed.
Second-Line Approach (Partial)
After allopurinol failure in this setting, the approach involves switching to an alternative urate-lowering agent that has demonstrated greater effectiveness in patients with chronic kidney disease. The choice of agent is directly constrained by the degree of renal impairment — not all options available in patients with preserved renal function apply here. The complete selection and sequencing are in the full protocol.
Treatment Targets
- Serum uric acid <6 mg/dL (360 mmol/L)
- Serum uric acid <5 mg/dL (300 mmol/L) for patients with severe gout, until total crystal dissolution
References
DOI: 10.1136/annrheumdis-2016-209707
- In patients with renal impairment, the allopurinol maximum dosage should be adjusted to creatinine clearance.
- If the SUA target cannot be achieved at this dose, the patient should be switched to febuxostat or given benzbromarone with or without allopurinol, except in patients with estimated glomerular filtration rate <30 mL/min.
- Febuxostat has been found more effective in patients with CKD than allopurinol given at doses adjusted to creatinine clearance and therefore can be used in these patients.
- Benzbromarone is not recommended for use in patients with eGFR <30 mL/min, but can be used in patients with moderate renal impairment because it is predominately metabolised by the liver.
- For patients on ULT, SUA level should be monitored and maintained to <6 mg/dL (360 mmol/L).
- A lower SUA target (<5 mg/dL; 300 mmol/L) to facilitate faster dissolution of crystals is recommended for patients with severe gout (tophi, chronic arthropathy, frequent attacks) until total crystal dissolution and resolution of gout.
View source ↗